Jefferies initiated coverage of Orchestra BioMed with a Buy rating and $14 price target. Orchestra is using strategic collaborations with established companies to bring breakthrough products to market, a relatively novel approach in medical technology, the analyst tells investors in a research note. The firm sees value in the company’s first two programs, BackBeat for hypertension and the Virtue SAB.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OBIO:
- Orchestra BioMed announces initiation of BACKBEAT study of AVIM therapy
- Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
- Orchestra Biomed Holdings Inc trading resumes
- Orchestra Biomed Holdings Inc trading halted, volatility trading pause
